Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Summary
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients with a cytologically or histologically confirmed locally advanced basal cell carcinoma. (Nodal involvement permitted) * Adult males or females 18 years of age or older at time of signing informed consent. All races and ethnicities are eligible, and no upper limit of age is specified. * Must have ability to comprehend and the willingness to sign written informed consent for study participation. * Patients must have at least one cutaneous tumor site amenable to direct and accurate measurement by ruler/calipers. * Patients may have received prior hedgehog inhibitor…
Interventions
- DrugVismodegib 150 MG Oral Capsule
Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Location
- Moffitt Cancer CenterTampa, Florida